Novocure

Yahoo Finance • 2 months ago

Form 13G NovoCure Ltd. For: 13 August

... Full story

Yahoo Finance • 2 months ago

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) on July 24, setting a price target of $... Full story

Yahoo Finance • 2 months ago

Novocure stock hits 52-week low at 10.88 USD

Novocure Ltd (NASDAQ:NVCR) stock has reached a new 52-week low, closing at 10.88 USD. The medical technology company, with a market capitalization of $1.22 billion, has seen its shares decline 62.65% year-to-date. According to InvestingPr... Full story

Yahoo Finance • 2 months ago

Strategic Education Becomes Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals a... Full story

Yahoo Finance • 2 months ago

NovoCure GAAP EPS of -$0.36 beats by $0.03, revenue of $158.8M beats by $4.6M

* NovoCure press release [https://seekingalpha.com/pr/20176390-novocure-reports-second-quarter-2025-financial-results] (NASDAQ:NVCR [https://seekingalpha.com/symbol/NVCR]): Q2 GAAP EPS of -$0.36 beats by $0.03. * Revenue of $158.8M (+5... Full story

Yahoo Finance • 3 months ago

NovoCure stock initiated with Buy rating at Ladenburg Thalmann

Investing.com - Ladenburg Thalmann initiated coverage on NovoCure Ltd. (NASDAQ:NVCR) with a Buy rating and a $30.00 price target on Tuesday. According to InvestingPro data, this target aligns with the broader analyst consensus, as the stoc... Full story

Yahoo Finance • 3 months ago

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $38.00 price target on NovoCure Ltd. (NASDAQ:NVCR) following positive trial results for its cancer treatment. Currently trading at $17.88, the stock shows potential upside acc... Full story

Yahoo Finance • 3 months ago

Novocure to Report Second Quarter 2025 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at... Full story

Yahoo Finance • 5 months ago

The Next Frontier to Treat Cancer: Electricity

Scientists are testing electric fields and pulses against a range of diseases including rheumatoid arthritis and brain cancer. Continue Reading View Comments... Full story

Yahoo Finance • 12 months ago

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results... Full story

Yahoo Finance • last year

Novocure to Report Second Quarter 2024 Financial Results

ROOT, Switzerland, July 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure manag... Full story

Yahoo Finance • last year

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone Patients treated with... Full story

Yahoo Finance • last year

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM Topline data to be presented Saturday, June 1, 2024 at the 2024 American Society of Clin... Full story

Yahoo Finance • 2 years ago

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

ROOT, Switzerland, January 04, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership a... Full story

Yahoo Finance • 2 years ago

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

ROOT, Switzerland, December 27, 2023--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive... Full story

Yahoo Finance • 2 years ago

11 Best Undervalued UK Stocks To Buy Now

In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story

Yahoo Finance • 2 years ago

Novocure Reports Third Quarter 2023 Financial Results

Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 ROOT, Switzerland, October 26, 2023--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended Sep... Full story

Yahoo Finance • 2 years ago

NovoCure (NASDAQ:NVCR investor three-year losses grow to 90% as the stock sheds US$229m this past week

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of NovoCure Limited (NASDAQ:NVCR) investors who have... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of Peloton Interactive, Inc. (NASDAQ: PTON), DZS Inc. (NASDAQ: DZSI), TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), and NovoCure Ltd. (NASDAQ: NVCR)

NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (NASDAQ: PTON) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations... Full story

Yahoo Finance • 2 years ago

Novocure Plummets 34% After Its Cancer Treatment Fails In Ovarian Cancer

Novocure said Monday its cancer treatment failed to make a difference for ovarian cancer patients, and NVCR stock plummeted. Continue reading... Full story